Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Revolution Medicines (RVMD) Income towards Parent Company: 2018-2024

Historic Income towards Parent Company for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to -$600.0 million.

  • Revolution Medicines' Income towards Parent Company fell 95.28% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$960.9 million, marking a year-over-year decrease of 69.46%. This contributed to the annual value of -$600.0 million for FY2024, which is 37.51% down from last year.
  • According to the latest figures from FY2024, Revolution Medicines' Income towards Parent Company is -$600.0 million, which was down 37.51% from -$436.4 million recorded in FY2023.
  • Revolution Medicines' Income towards Parent Company's 5-year high stood at -$108.2 million during FY2020, with a 5-year trough of -$600.0 million in FY2024.
  • In the last 3 years, Revolution Medicines' Income towards Parent Company had a median value of -$436.4 million in 2023 and averaged -$428.4 million.
  • Data for Revolution Medicines' Income towards Parent Company shows a maximum YoY slumped of 126.92% (in 2020) over the last 5 years.
  • Revolution Medicines' Income towards Parent Company (Yearly) stood at -$108.2 million in 2020, then tumbled by 72.98% to -$187.1 million in 2021, then crashed by 32.93% to -$248.7 million in 2022, then plummeted by 75.46% to -$436.4 million in 2023, then plummeted by 37.51% to -$600.0 million in 2024.